Literature DB >> 15345206

Neuroendocrine Tumors of the Pancreas.

James M. McLoughlin1, Joseph A. Kuhn, Jeffrey T. Lamont.   

Abstract

Neuroendocrine tumors (NETs) are rare tumors of the endocrine pancreas that require a high degree of suspicion for timely diagnosis. Diagnosis is often delayed due to the nonspecific and intermittent presentation of symptoms. As many as 45% to 55% of tumors are nonfunctional and are typically diagnosed secondary to mass effect related symptoms or found incidentally. Functional tumors often are symptom specific and are diagnosed at an earlier stage than nonfunctional tumors. The challenging aspects of treating NETs are localizing the tumors, treating extensive or metastatic disease, and palliating symptoms. Most NETs have an indolent course, and aggressive multimodality treatment is often indicated and encouraged.

Entities:  

Year:  2004        PMID: 15345206     DOI: 10.1007/s11938-004-0048-7

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  43 in total

1.  Pancreatic islet cell tumors.

Authors:  T A Broughan; J D Leslie; J M Soto; R E Hermann
Journal:  Surgery       Date:  1986-06       Impact factor: 3.982

2.  Lethality of multiple endocrine neoplasia type I.

Authors:  G M Doherty; J A Olson; M M Frisella; T C Lairmore; S A Wells; J A Norton
Journal:  World J Surg       Date:  1998-06       Impact factor: 3.352

3.  Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.

Authors:  Steven N Hochwald; Sui Zee; Kevin C Conlon; Roberto Colleoni; Otway Louie; Murray F Brennan; David S Klimstra
Journal:  J Clin Oncol       Date:  2002-06-01       Impact factor: 44.544

Review 4.  Octreotide.

Authors:  S W Lamberts; A J van der Lely; W W de Herder; L J Hofland
Journal:  N Engl J Med       Date:  1996-01-25       Impact factor: 91.245

Review 5.  Current approach to the management of gastrinoma and insulinoma in adults with multiple endocrine neoplasia type I.

Authors:  M Mignon; P Ruszniewski; P Podevin; L Sabbagh; G Cadiot; D Rigaud; S Bonfils
Journal:  World J Surg       Date:  1993 Jul-Aug       Impact factor: 3.352

Review 6.  Current surgical management of Zollinger-Ellison syndrome (ZES) in patients without multiple endocrine neoplasia-type 1 (MEN1).

Authors:  Jeffrey A Norton; Robert T Jensen
Journal:  Surg Oncol       Date:  2003-08       Impact factor: 3.279

7.  Nonfunctioning pancreatic endocrine tumors: a multicenter clinical study.

Authors:  Lucio Gullo; Marina Migliori; Massimo Falconi; Paolo Pederzoli; Rossella Bettini; Riccardo Casadei; Gianfranco Delle Fave; Vito D Corleto; Claudio Ceccarelli; Donatella Santini; Paola Tomassetti
Journal:  Am J Gastroenterol       Date:  2003-11       Impact factor: 10.864

8.  Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients.

Authors:  P Ruszniewski; P Rougier; A Roche; P Legmann; A Sibert; S Hochlaf; M Ychou; M Mignon
Journal:  Cancer       Date:  1993-04-15       Impact factor: 6.860

9.  Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma.

Authors:  D L Fraker; J A Norton; H R Alexander; D J Venzon; R T Jensen
Journal:  Ann Surg       Date:  1994-09       Impact factor: 12.969

Review 10.  Islet cell tumors of the pancreas: the medical oncologist's perspective.

Authors:  R Brentjens; L Saltz
Journal:  Surg Clin North Am       Date:  2001-06       Impact factor: 3.537

View more
  2 in total

Review 1.  Liver transplantation for metastatic neuroendocrine tumor: a case report and review of the literature.

Authors:  Wojciech C Blonski; K Rajender Reddy; Abraham Shaked; Evan Siegelman; David C Metz
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

2.  Concomitant endometrial and pancreatic cancers.

Authors:  S Michelle Shiller; Shawna L Bull Phelps; Jeffrey P Lamont; Granger R Scruggs
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.